Overview

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of the bevacizumab and capecitabine combination in frail patients with untreated metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Oncology Research International
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Capecitabine